Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
In brief
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Key facts
- Study ID
- NCT06545942
- Run by
- MOMA Therapeutics
- People needed
- 220
- Starts
- 2024-08-13
- Expected to finish
- 2027-11-30
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigative Site #118 — Newcastle upon Tyne, United Kingdom (enrolling)
- Investigative Site #101 — La Jolla, California, United States (enrolling)
- Investigative Site #115 — Madrid, Spain (enrolling)
- Investigative Site #113 — London, United Kingdom (enrolling)
- Investigative Site #117 — Manchester, United Kingdom (enrolling)
- Investigative Site #108 — Goodyear, Arizona, United States (enrolling)
- Investigative Site #104 — Lake Mary, Florida, United States (enrolling)
- Investigative Site #110 — St Louis, Missouri, United States (enrolling)
- Investigative Site #103 — New York, New York, United States (enrolling)
- Investigative Site #106 — New York, New York, United States (enrolling)
- Investigative Site #109 — Philadelphia, Pennsylvania, United States (enrolling)
- Investigative Site #102 — Nashville, Tennessee, United States (enrolling)
- Investigative Site #114 — Barcelona, Spain (enrolling)
- Investigative Site #116 — Barcelona, Spain (enrolling)
- Investigative Site #111 — San Francisco, California, United States
- Investigative Site #112 — Fairfax, Virginia, United States
- Investigative Site #105 — San Antonio, Texas, United States
- Investigative Site #107 — Myrtle Beach, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.